SE57-1 inhibitors belong to a class of molecules that are designed to modulate specific enzymatic activity, particularly in pathways that involve complex protein-protein interactions. These inhibitors function by binding to a specific target, SE57-1, which is an important regulatory enzyme or protein involved in intracellular signaling cascades or other vital biochemical pathways. The mechanism of inhibition typically relies on competitive, non-competitive, or allosteric interactions with SE57-1, leading to a reduction in its enzymatic efficiency. The molecular structure of SE57-1 inhibitors is often designed with high specificity, allowing them to engage with the active or regulatory site of the target molecule. By modulating SE57-1 activity, these inhibitors can profoundly affect downstream biochemical processes, including metabolic regulation or signal transduction.
The development of SE57-1 inhibitors often involves detailed studies into the three-dimensional conformation of SE57-1, as well as the specific residues involved in its enzymatic activity. Structural biology techniques such as X-ray crystallography and NMR are frequently employed to understand the binding pocket of SE57-1, which aids in the rational design of inhibitors with optimal affinity and selectivity. Additionally, computational modeling and in vitro assays are essential for optimizing the inhibitor's properties, including its solubility, stability, and binding kinetics. The physicochemical properties of SE57-1 inhibitors, such as their hydrophobicity, charge distribution, and molecular size, play critical roles in determining their binding affinity and interaction with the target.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Stabilizes microtubules, affecting cell division and trafficking processes. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Disrupts microtubule polymerization, impacting cell division and cytoskeletal dynamics. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Inhibits actin polymerization, affecting cell shape and motility. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
An HDAC inhibitor, which could affect gene expression, potentially influencing CCDC68. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
An HDAC inhibitor, used in cancer therapy, might affect CCDC68-related pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, could impact signaling pathways, potentially affecting CCDC68. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, which might indirectly affect proteins involved in cell growth and survival. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Inhibits autophagy and lysosomal degradation, potentially affecting protein turnover related to CCDC68. | ||||||